Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improvi

Jeongkuk SEO; Won-Seog KIM; Jin-Seok KIM; Seok-Jin KIM; Jae-Hoon LEE; Jun-Shik HONG; Gyeong-Won LEE; Sung-Yong OH; Ji-Hyun LEE; Dok-Hyun YOON; Won-Sik LEE; Hyo-Jung KIM; Jae-Yong KWAK; Hye-Jin KANG; Jae-Cheol JO; Yong PARK; Ho-Sup LEE; Hyo-Jin KIM; Cheolwon SUH.
Blood Research ; : 200-206, 2017.
Artículo en Inglés | WPRIM | ID: wpr-185278

Documentos relacionados

  1. Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.
  2. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
  3. A new frontier for R-CHOP: is two better than one?
  4. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
  5. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.
  6. The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
  7. Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study.
  8. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
  9. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
  10. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.